PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33831397-5 2021 Here, we showed that HHT synergizes with a selective next-generation FLT3 inhibitor, quizartinib, to inhibit cell growth/viability and induce cell-cycle arrest and apoptosis in FLT3-ITD AML cells in vitro, significantly inhibit acute myeloid leukemia progression in vivo, and substantially prolong survival of mice-bearing human FLT3-ITD AML. quizartinib 85-96 FMS-like tyrosine kinase 3 Mus musculus 69-73 34288692-5 2021 The compounds blocked the proliferation of AML cell lines harboring oncogenic FLT3-ITD mutations with remarkable IC50 values, which were comparable to the approved FLT3 inhibitor quizartinib. quizartinib 179-190 FMS-like tyrosine kinase 3 Mus musculus 78-82 34288692-5 2021 The compounds blocked the proliferation of AML cell lines harboring oncogenic FLT3-ITD mutations with remarkable IC50 values, which were comparable to the approved FLT3 inhibitor quizartinib. quizartinib 179-190 FMS-like tyrosine kinase 3 Mus musculus 164-168 34362479-7 2021 Under the exposure of FLT3 inhibitor AC220, the IC50 values was 0.183, 0.446 and 0.836 nmol/L, and apoptosis rates was 88.6%, 34.2% and 16.1%, respectively. quizartinib 37-42 FMS-like tyrosine kinase 3 Mus musculus 22-26 34362479-8 2021 CONCLUSION: FLT3-ITD mutant expressed cell strains with longer ITD show higher capacity of proliferation and higher tolerance to AC220 treatment. quizartinib 129-134 FMS-like tyrosine kinase 3 Mus musculus 12-16 32999332-3 2020 Treatment of mice on a HFD with Quizartinib, a potent inhibitor of FLT3 phosphorylation, inhibits the JAK3/STAT3, signaling and finally antagonizes the accelerated development of AML that occurred following the HFD regimen. quizartinib 32-43 FMS-like tyrosine kinase 3 Mus musculus 67-71 30590794-4 2019 Methods: To test the effect on CD103+ DCs and kidney injury of inhibition of Flt3, we used a selective Flt3 inhibitor (AC220) to treat mice with AN. quizartinib 119-124 FMS-like tyrosine kinase 3 Mus musculus 77-81 32629802-2 2020 Quizartinib, a potent FLT3 inhibitor, induced apoptosis in FLT3-ITD-AML, while LY2510924 blocked surface CXCR4 without inducing apoptosis. quizartinib 0-11 FMS-like tyrosine kinase 3 Mus musculus 22-26 32215183-5 2020 When quizartinib was administered to mice bearing FLT3-ITD mutated tumors, AC886 was rapidly detected and tumor regression was observed at doses of >=1 mg/kg without severe body weight loss. quizartinib 5-16 FMS-like tyrosine kinase 3 Mus musculus 50-54 30590794-4 2019 Methods: To test the effect on CD103+ DCs and kidney injury of inhibition of Flt3, we used a selective Flt3 inhibitor (AC220) to treat mice with AN. quizartinib 119-124 FMS-like tyrosine kinase 3 Mus musculus 103-107 30590794-10 2019 Conclusion: Flt3 inhibitor AC220 effectively reduced kidney injury in AN mice, suggesting that this inhibitor might be a useful pharmaceutical agent to treat CKD. quizartinib 27-32 FMS-like tyrosine kinase 3 Mus musculus 12-16 30553002-0 2019 P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice. quizartinib 125-136 FMS-like tyrosine kinase 3 Mus musculus 110-114 30923103-3 2019 Here, we investigated mechanisms dampening the response to the FLT3 inhibitor quizartinib, which is specific to the hematopoietic niche. quizartinib 78-89 FMS-like tyrosine kinase 3 Mus musculus 63-67 30923103-4 2019 Using AML primary samples and cell lines, we demonstrate that convergent signals from the hematopoietic microenvironment drive FLT3-ITD cell resistance to quizartinib through the expression and activation of the tyrosine kinase receptor AXL. quizartinib 155-166 FMS-like tyrosine kinase 3 Mus musculus 127-131 30923103-7 2019 Finally, in a xenograft mouse model, inhibition of AXL significantly increased the response of FLT3-ITD cells to quizartinib exclusively within a bone marrow environment. quizartinib 113-124 FMS-like tyrosine kinase 3 Mus musculus 95-99 30770553-9 2019 Finally, we determined that combined treatment of NSG mice engrafted with FLT3-ITD + MV4-11 AML cells with 8-Cl-Ado and the FLT3 inhibitor AC220 (quizartinib) synergistically enhanced survival, compared with that of mice treated with the individual drugs, suggesting a potentially effective approach for FLT3-ITD AML patients. quizartinib 146-157 FMS-like tyrosine kinase 3 Mus musculus 74-78 30553002-1 2019 Quizartinib, a second-generation FLT3 inhibitor, is in clinical development for the treatment of acute myeloid leukemia. quizartinib 0-11 FMS-like tyrosine kinase 3 Mus musculus 33-37 29187377-3 2018 Recently, a selective FLT3 inhibitor, quizartinib, demonstrated favorable outcomes in clinical studies. quizartinib 38-49 FMS-like tyrosine kinase 3 Mus musculus 22-26 29074603-5 2018 Concurrent treatment with AZD1208 and the FLT3 inhibitor quizartinib decreased growth of MV4-11 cells, with FLT3-ITD, in mouse xenografts, and prolonged survival, enhanced apoptosis of FLT3-ITD primary AML blasts, but not FLT3-WT blasts or remission marrow cells, and decreased FLT3-ITD AML blast colony formation. quizartinib 57-68 FMS-like tyrosine kinase 3 Mus musculus 108-112 28794285-0 2017 Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib. quizartinib 83-94 FMS-like tyrosine kinase 3 Mus musculus 68-72 28794285-2 2017 We found that short-term exposure of mice to the FLT3 inhibitor quizartinib induced the transient quiescence of multipotent progenitors (MPPs). quizartinib 64-75 FMS-like tyrosine kinase 3 Mus musculus 49-53 27387666-0 2016 Internal Tandem Duplication in FLT3 Attenuates Proliferation and Regulates Resistance to the FLT3 Inhibitor AC220 by Modulating p21Cdkn1a and Pbx1 in Hematopoietic Cells. quizartinib 108-113 FMS-like tyrosine kinase 3 Mus musculus 31-35 27387666-0 2016 Internal Tandem Duplication in FLT3 Attenuates Proliferation and Regulates Resistance to the FLT3 Inhibitor AC220 by Modulating p21Cdkn1a and Pbx1 in Hematopoietic Cells. quizartinib 108-113 FMS-like tyrosine kinase 3 Mus musculus 93-97 27387666-7 2016 When FLT3-ITD was antagonized with AC220, a selective inhibitor of FLT3-ITD, p21 expression was decreased coincident with Pbx1 mRNA up-regulation and a rapid decline in the number of viable FLT3-ITD+ Ba/F3 cells; however, the cells eventually became refractory to AC220. quizartinib 35-40 FMS-like tyrosine kinase 3 Mus musculus 5-9 27387666-7 2016 When FLT3-ITD was antagonized with AC220, a selective inhibitor of FLT3-ITD, p21 expression was decreased coincident with Pbx1 mRNA up-regulation and a rapid decline in the number of viable FLT3-ITD+ Ba/F3 cells; however, the cells eventually became refractory to AC220. quizartinib 35-40 FMS-like tyrosine kinase 3 Mus musculus 67-71 27387666-7 2016 When FLT3-ITD was antagonized with AC220, a selective inhibitor of FLT3-ITD, p21 expression was decreased coincident with Pbx1 mRNA up-regulation and a rapid decline in the number of viable FLT3-ITD+ Ba/F3 cells; however, the cells eventually became refractory to AC220. quizartinib 35-40 FMS-like tyrosine kinase 3 Mus musculus 67-71 29854425-3 2018 We found that mice deficient in Flt3 or mice that received an Flt3 inhibitor (AC220) showed significantly reduced areas of ischemia-induced retinal neovascularization (RNV) and laser-induced choroidal NV (CNV) (P < 0.05). quizartinib 78-83 FMS-like tyrosine kinase 3 Mus musculus 62-66 29209657-0 2017 Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy. quizartinib 71-82 FMS-like tyrosine kinase 3 Mus musculus 56-60 29209657-2 2017 Our recent work outlines a strategy to prevent chemotherapy-induced myelosuppression by administering a priming dose of the FMS-Like Tyrosine kinase 3 (FLT3) inhibitor quizartinib. quizartinib 168-179 FMS-like tyrosine kinase 3 Mus musculus 124-150 29209657-2 2017 Our recent work outlines a strategy to prevent chemotherapy-induced myelosuppression by administering a priming dose of the FMS-Like Tyrosine kinase 3 (FLT3) inhibitor quizartinib. quizartinib 168-179 FMS-like tyrosine kinase 3 Mus musculus 152-156 29212189-2 2017 Quizartinib (AC220), a potent class III receptor tyrosine kinase inhibitor (TKI), was synthesized to selectively inhibit FMS-like tyrosine kinase-3 (FLT3), a target in the treatment of acute myeloid leukemia (AML). quizartinib 0-11 FMS-like tyrosine kinase 3 Mus musculus 121-147 29212189-2 2017 Quizartinib (AC220), a potent class III receptor tyrosine kinase inhibitor (TKI), was synthesized to selectively inhibit FMS-like tyrosine kinase-3 (FLT3), a target in the treatment of acute myeloid leukemia (AML). quizartinib 0-11 FMS-like tyrosine kinase 3 Mus musculus 149-153 29212189-2 2017 Quizartinib (AC220), a potent class III receptor tyrosine kinase inhibitor (TKI), was synthesized to selectively inhibit FMS-like tyrosine kinase-3 (FLT3), a target in the treatment of acute myeloid leukemia (AML). quizartinib 13-18 FMS-like tyrosine kinase 3 Mus musculus 121-147 29212189-2 2017 Quizartinib (AC220), a potent class III receptor tyrosine kinase inhibitor (TKI), was synthesized to selectively inhibit FMS-like tyrosine kinase-3 (FLT3), a target in the treatment of acute myeloid leukemia (AML). quizartinib 13-18 FMS-like tyrosine kinase 3 Mus musculus 149-153 29212189-3 2017 Quizartinib is currently under clinical trials for FLT3 ITD and wild-type AML and is tested in combination with chemotherapy. quizartinib 0-11 FMS-like tyrosine kinase 3 Mus musculus 51-55 22990016-0 2012 Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling. quizartinib 15-20 FMS-like tyrosine kinase 3 Mus musculus 0-4 22990016-0 2012 Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling. quizartinib 15-20 FMS-like tyrosine kinase 3 Mus musculus 117-121